首页 > Autophagy > TAM Receptor
TAM Receptor
T1797 XL184(Cabozantinib malate) Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
T1968 UNC2250 UNC2250 is an effective and specific Mer inhibitor (IC50=1.7 nM).
T2005 TP0903 TP-0903 is a potent and selective Axl kinase inhibitor.
T2311 LDC1267 LDC1267 is a excellently specific TAM(Tyro3, Axl and Mer) kinase inhibitor, for Mer( IC50<5 nM), Tyro3(IC50=8 nM), and Axl(IC50=29 nM).
T2586 Cabozantinib Cabozantinib is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
T2620 G-749 G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
T2629 UNC2881 UNC2881 is a specific Mer tyrosine kinase inhibitor (IC50: 4.3 nM). It is about 83- and 58-fold higher selectivity than Axl and Tyro3, respectively.
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
T3274 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
T3512 S49076 HCl S49076 is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo. In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells blocke
T4213 NCT-503 NCT-503 is an inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), inhibiting serine synthesis from 3-phosphoglycerate in cells.
T6121 Tepotinib (EMD 1214063) Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activity.
T6269 R428 R428 (BGB324), a selective inhibitor of Axl(IC50=14 nM), has been investigated for the treatment of non-small cell lung cancer.
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T6982 SGI-7079 SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
T7007 UNC-2025 UNC-2025( IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
T4426 CEP-40783 (RXDX-106) CEP-40783 is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
T4409 Gilteritinib Gilteritinib is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib showed strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical tria
T4419 UNC2025 2HCl (1429881-91-3(free base)) UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科研,我们不为任何其他用途提供产品和服务